BR112017006708A2 - indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue - Google Patents

indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue

Info

Publication number
BR112017006708A2
BR112017006708A2 BR112017006708A BR112017006708A BR112017006708A2 BR 112017006708 A2 BR112017006708 A2 BR 112017006708A2 BR 112017006708 A BR112017006708 A BR 112017006708A BR 112017006708 A BR112017006708 A BR 112017006708A BR 112017006708 A2 BR112017006708 A2 BR 112017006708A2
Authority
BR
Brazil
Prior art keywords
mono
compounds
inhibitors
dengue viral
viral replication
Prior art date
Application number
BR112017006708A
Other languages
English (en)
Inventor
Didier M Marchand Arnaud
Rudolf Romanie Kesteleyn Bart
Alice Marie-Eve Bardiot Dorothee
Bonfanti Jean-François
Jean-Marie Bernard Raboisson Pierre
Hugo Maria Jonckers Tim
Original Assignee
Janssen Pharmaceuticals Inc
Katholieke Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54207512&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017006708(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals Inc, Katholieke Univ filed Critical Janssen Pharmaceuticals Inc
Publication of BR112017006708A2 publication Critical patent/BR112017006708A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

a presente invenção diz respeito a compostos de indol mono- ou dissubstituídos da fórmula (i) que são úteis para prevenir ou tratar infeções virais de dengue e se relaciona também com os referidos compostos para uso como um medicamento, mais preferencialmente para uso como um medicamento para tratar ou prevenir infeções virais de dengue. a presente invenção relaciona-se além disso com composições farmacêuticas ou preparações de combinação dos compostos, com as composições ou preparações para uso como um medicamento, mais preferencialmente para a prevenção ou tratamento de infeções virais de dengue. a invenção relaciona-se também com processos para preparação dos compostos.
BR112017006708A 2014-10-01 2015-09-30 indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue BR112017006708A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14187373 2014-10-01
EP15156073 2015-02-23
PCT/EP2015/072534 WO2016050831A1 (en) 2014-10-01 2015-09-30 Mono- or di-substituted indoles as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
BR112017006708A2 true BR112017006708A2 (pt) 2017-12-26

Family

ID=54207512

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006708A BR112017006708A2 (pt) 2014-10-01 2015-09-30 indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue

Country Status (30)

Country Link
US (1) US10206902B2 (pt)
EP (1) EP3201177B1 (pt)
JP (1) JP6701185B2 (pt)
KR (1) KR102478309B1 (pt)
CN (1) CN107001265B (pt)
AU (1) AU2015326920A1 (pt)
BR (1) BR112017006708A2 (pt)
CA (1) CA2958022A1 (pt)
CL (1) CL2017000742A1 (pt)
CY (1) CY1121972T1 (pt)
DK (1) DK3201177T3 (pt)
EA (1) EA033845B1 (pt)
ES (1) ES2711117T3 (pt)
HR (1) HRP20190139T1 (pt)
HU (1) HUE042628T2 (pt)
IL (1) IL251401A0 (pt)
LT (1) LT3201177T (pt)
MA (1) MA40769B1 (pt)
ME (1) ME03344B (pt)
MX (1) MX2017004298A (pt)
PH (1) PH12017500503A1 (pt)
PL (1) PL3201177T3 (pt)
PT (1) PT3201177T (pt)
RS (1) RS58394B1 (pt)
SG (1) SG11201702464WA (pt)
SI (1) SI3201177T1 (pt)
TW (1) TW201619130A (pt)
UY (1) UY36339A (pt)
WO (1) WO2016050831A1 (pt)
ZA (1) ZA201702299B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR102457840B1 (ko) 2014-10-01 2022-10-21 메르크 파텐트 게엠베하 보론산 유도체
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
MX2018011784A (es) 2016-03-31 2019-02-13 Janssen Pharmaceuticals Inc Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue.
BR112018068956A2 (pt) * 2016-04-01 2019-01-22 Janssen Pharmaceuticals Inc derivados do composto indol substituídos como inibidores da replicação viral da dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PE20200342A1 (es) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
ES2929667T3 (es) 2017-05-22 2022-11-30 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CN114989131B (zh) * 2022-05-30 2023-10-24 云南大学 N’-(2-(苯并[1,3]二氧戊烷-5-基)酰基)芳酰肼类化合物及其合成和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
AU2009283195A1 (en) * 2008-08-18 2010-02-25 Yale University MIF modulators
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
SG11201702463YA (en) * 2014-10-01 2017-04-27 Janssen Pharmaceuticals Inc Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Also Published As

Publication number Publication date
US10206902B2 (en) 2019-02-19
KR102478309B1 (ko) 2022-12-15
MA40769B1 (fr) 2019-03-29
EA033845B1 (ru) 2019-12-02
TW201619130A (zh) 2016-06-01
EA201790700A1 (ru) 2017-08-31
ES2711117T3 (es) 2019-04-30
LT3201177T (lt) 2019-03-12
IL251401A0 (en) 2017-05-29
WO2016050831A1 (en) 2016-04-07
CL2017000742A1 (es) 2017-11-03
US20170224658A1 (en) 2017-08-10
HRP20190139T1 (hr) 2019-03-22
JP6701185B2 (ja) 2020-05-27
EP3201177B1 (en) 2018-11-21
CN107001265A (zh) 2017-08-01
CY1121972T1 (el) 2020-10-14
ME03344B (me) 2019-10-20
CN107001265B (zh) 2021-06-15
JP2017531638A (ja) 2017-10-26
SG11201702464WA (en) 2017-04-27
AU2015326920A1 (en) 2017-03-02
DK3201177T3 (en) 2019-03-04
UY36339A (es) 2016-04-01
HUE042628T2 (hu) 2019-07-29
PL3201177T3 (pl) 2019-05-31
PH12017500503A1 (en) 2017-08-30
PT3201177T (pt) 2019-02-12
KR20170063675A (ko) 2017-06-08
RS58394B1 (sr) 2019-04-30
SI3201177T1 (sl) 2019-05-31
CA2958022A1 (en) 2016-04-07
MA40769A (fr) 2017-09-09
EP3201177A1 (en) 2017-08-09
MX2017004298A (es) 2017-07-19
ZA201702299B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
BR112017006708A2 (pt) indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
BR112018068956A2 (pt) derivados do composto indol substituídos como inibidores da replicação viral da dengue
PH12018502016A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
CO2018003369A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
BR112018068676A2 (pt) derivados de indol substituídos como inibidores da replicação viral do dengue
CO2018003471A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements